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2Abstract23
Two series of fibers containing the active ingredients acyclovir, ciprofloxacin and24
cyanocobalamin, and combinations of these drugs, were prepared by electrospinning. One set25
used the hydrophilic poly(vinylpyrrolidone) (PVP) as the filament-forming polymer, while the26
other used the slow-dissolving poly(ε-caprolactone) (PCL). The fibers were found to have 27
cylindrical morphologies, although there was evidence for solvent occlusion with the PVP28
systems and for some drug particles in the PCL case. The active ingredients were generally29
present in the amorphous physical form in the case of PVP, but evidence of crystallinity was30
observed with PCL. The existence of intermolecular interactions between the drugs and31
polymers was proven using simple molecular modeling calculations. Drug release from the32
various fibers was tested in a validated in vitro outflow model of the eye, and the fiber33
formulations found to be capable of extending drug release. We thus conclude that electrospun34
matrices such as those prepared in this work have potential for use as intravitreal implants.35
36
Keywords37
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31. Introduction44
Cytomegalovirus (CMV) infections are a major clinical problem in patients with AIDS. Their main45
manifestation in AIDS patients is retinitis, which accounts for 20-30% of all cases (Pollard,46
1996). Common symptoms of CMV retinitis include visual field defects with decreased acuity,47
the presence of floaters, and photophobia. Complications arise when retinitis is localized near48
the macula, which can lead to loss of vision and to hemorrhages replaced eventually by thin49
atrophic scar tissue and inflammation (Jouan and Katlama, 1999). Most ocular drugs when50
given by topical administration are rapidly cleared by the aqueous humor flowing into the51
anterior chamber and flushing the drug out via the trabecular meshwork, should they permeate52
the cornea. The drug will often therefore fail to reach reproducible therapeutic levels near the53
retina (Haghjou et al., 2013). Intravitreal (IVT) injection can provide adequate drug54
concentrations in the posterior segment. Unfortunately drugs in solution can rapidly clear55
within hours from the posterior cavity upon IVT injection. This reduces efficacy and frequent56
injections are required, which can lead to undesirable side effects, and reduce patient57
compliance (Short, 2008).58
59
To solve the general problem of fast ocular clearance times, new strategies are being60
investigated to deliver drugs as intravitreal implants specifically designed to prolong release.61
One example is Vitrasert® (Bausch & Lomb Inc, Rochester, NY, USA), a ganciclovir loaded62
intravitreal implant approved by the US Food and Drug Administration and administered for the63
treatment of CMV retinitis. The implant is primarily made of ethylene-vinyl acetate and64
polyvinyl alcohol, and the drug is released over a period of 6-8 months (Kuno and Fujii, 2011).65
66
There are a number of drug candidates that can be used to treat ocular infections. Acyclovir67
(ACY) is an effective antiviral agent but is only slightly soluble in water. This limits its use in the68
4eye since it is challenging to prepare a solution with sufficient solubility to exert a therapeutic69
effect. Ciprofloxacin (CIP) is widely used to prevent and cure bacterial infections, and thus can70
be used with ACY to provide broad-spectrum anti-pathogenic activity. It too has very poor71
water solubility. Cyanocobalamin (vitamin B12) has been reported to repair damage to the eye,72
and is used as a reparative agent in some eye drops (e.g. Sante Beautéye (Santen73
Pharmaceutical Co, 2013)). A formulation containing all three ingredients, with solubility74
enhancement for ACY and CIP, would thus be a useful addition to the gamut of treatments for75
viral diseases of the eye.76
77
Various strategies can be applied to increase the solubility and dissolution rate of poorly soluble78
drugs; one popular approach is to prepare amorphous dispersions of the active pharmaceutical79
ingredient (API) in a polymer matrix. The formation of such a solid solution or solid suspension80
removes the lattice energy barrier to dissolution, and the polymer carrier additionally helps to81
stabilize the amorphous form by preventing the API molecules from crystallizing. One method82
which has been widely explored to generate such pharmaceutical composites is electrospinning83
(Chakraborty et al., 2009; Williams et al., 2012). This approach is attractive in its simplicity. A84
co-dissolving solution of a polymer and an API is first prepared in a volatile solvent. This is then85
loaded into a syringe fitted with a metal needle (the spinneret). The polymer solution is ejected86
from the syringe towards a metal collector plate at a constant rate, controlled using a syringe87
pump. A high potential difference is applied between the spinneret (positive) and collector88
(grounded), causing rapid evaporation of the solvent and the formation of a non-woven mesh89
of polymer/API fibers, often with dimensions on the nanoscale.90
91
Electrospinning has been used to prepare numerous formulations with enhanced92
solubility/dissolution characteristics, and ACY, CIP and B12 have all been previously processed93
5in this manner. Only a single publication relating to B12 electrospinning could be found in the94
literature, focused on preparing temperature-sensitive release systems based on poly(ethylene95
oxide) and poly(isopropylacrylamide) (Song et al., 2011). A number of reports of CIP spinning96
exist, focused primarily on would dressings (El-Shanshory et al., 2015; Unnithan et al., 2012),97
oral hygiene (Bottino et al., 2014) or urinary devices (Macocinschi et al., 2015): no studies have98
been reported targeted at ocular drug delivery.99
100
Yu et al. have undertaken several investigations into ACY fibers, using both slow and fast101
dissolving polymers. Core/shell fibers of poly(vinyl pyrrolidone) (PVP) were prepared with a102
shell containing PVP, sodium dodecyl sulfate (as a permeation enhancer) and sucralose (a flavor103
enhancer), and a PVP/ACY core (Yu et al., 2011). These were designed for oral application, and104
found to release all the incorporated drug within 1 minute. Analogous systems and results were105
obtained using electrospraying, a technique closely related to electrospinning which produces106
particles instead of fibers (Liu et al., 2014). Sustained release systems loaded with ACY have107
also been prepared with poly(acrylonitrile) as the carrier polymer (Chen and Yu, 2010; Yu et al.,108
2010).109
110
All of the abovementioned systems were prepared with applications other than the ocular field111
in mind. In this work, we sought to develop electrospun systems to allow effective healing of112
viral eye infections. ACY, CIP and B12 (see Figure 1) were first spun individually before113
combination formulations were prepared. In order to explore drug release in a representative114
environment, functional performance assays were performed using the recently reported PK-115
Eye model (Awwad et al., 2015), depicted in Figure 2. This aims to provide a reliable in vitro116
proxy for drug dissolution and distribution in the eye. There is no model for the eye given in the117
pharmacopoeia, and the few in vitro models reported in the literature are limited in that they118
6do not mimic the human eye in terms of scale and/or mass transfer. While in vitro models are119
of course not completely representative of what occurs in vivo, they are widely used in120
formulation to predict in vivo performance. The PK-Eye is currently being used to develop in121
vitro – in vivo correlations for ocular formulations and the use of this model avoids the use of122
animals, which are not generally predictive of human ocular pharmacokinetics. To plot a123
reliable time-concentration curve for ocular pharmacokinetics at least 36 rabbits would be124
required, which is unacceptable for drug screening and inconsistent with the 3Rs philosophy.125
The PK-Eye is specifically designed as a two-compartment model scaled to human dimensions126
and mimics the intraocular aqueous outflow through the anterior route. In this study, the API-127
loaded fibers were tested in the posterior cavity of the PK-Eye to observe their release128
behavior.129
130
Figure 1: The chemical structures of acyclovir, ciprofloxacin and cyanocobalamin.131
132
133
7134
Figure 2: The PK-Eye model. Adapted from Awwad et al. 2015.135
136
2. Experimental section137
2.1 Materials138
Polyvinylpyrrolidone K60 (PVP; molecular weight 360,000 Da), polycaprolactone (PCL;139
molecular weight 70,000 Da), acyclovir (ACY), ciprofloxacin (CIP), chloroform, and N,N-140
dimethylformamide (DMF) were procured from Sigma-Aldrich (Gillingham, UK), while141
cyanocobalamin (vitamin B12) and methanol (AR grade) were sourced from Fisher Scientific142
(Loughborough, UK).143
144
2.2 Electrospinning145
Solutions for electrospinning (ES) were prepared by dissolving the required amount of drug and146
polymer in DMF/chloroform (for PVP fibers; 1:1 v/v) or chloroform/methanol (for PCL fibers;147
1:1 v/v). The API was added to 10 mL of solvent in a clear glass vial and stirred at room148
temperature (RT) for ca. 2 h until complete dissolution was achieved. After this, 1900 mg PVP149
or 750 mg PCL was slowly added and the resultant solutions stirred overnight at RT. During150
stirring, the glass vials were sealed with a rubber cup to avoid solvent evaporation.151
152
8For ES, the API/polymer solution was loaded into a 5 mL plastic syringe to which a stainless153
steel needle (spinneret; 18G, internal diameter 0.84 mm; Nordson EFD, Dunstable, UK) was154
attached. A high voltage DC power supply (HCP 35-35,000, FuG Electronic, Rosenheim,155
Germany) was employed to provide a high voltage between the spinneret and a metal collector156
plate. For all experiments, the applied voltage was 12 kV, the spinneret-to-collector distance 15157
cm and the flow rate 0.5 mL h-1. All processes were conducted at ambient temperature and158
pressure (22 ± 3 °C, and 30 ± 5 % relative humidity). After manufacturing, samples were159
wrapped in aluminum foil and stored in a desiccator for at least 12 h prior to analysis. Silica gel160
was used as desiccant, maintaining the relative humidity inside the desiccator below 25 %.161
Details of the spinning solutions prepared and the resultant fiber compositions are given in162
Table 1.163
164
Table 1: Details of the spinning solutions and fibers prepared.165
Polymer Drug FormulationID
Polymer conc
in solution
(% w/v)
API conc in
solution
(% w/v)
Polymer conc
in fibers
(% w/w)
API conc in
fibers
(% w/w)
PVP
ACY PVP-ACY 19 1 95 5
CIP PVP-CIP 19 0.3 98.4 1.6
B12 PBP-B12 19 0.2 99.0 1.0
ACY
B12
CIP
PVP-ABC 19
1
0.3
0.2
92.7
4.9
1.5
1.0
PCL
ACY PCL-ACY 7.5 1 88.2 11.8
CIP PCL-CIP 7.5 0.3 96.2 3.8
B12 PCL-B12 7.5 0.2 97.4 2.6
ACY -CIP PCL-AC 7.5 10.3 85.2
11.4
3.4
ACY-B12-CIP PCL-ABC 7.5
1
0.3
0.2
83.3
11.1
3.3
2.2
166
92.3 Characterization167
2.3.1 Scanning electron microscopy168
Scanning electron microscopy (SEM) was used to investigate the morphology of the fibers169
prepared. Samples were cut from the fiber mats and adhered onto aluminium SEM stubs using170
carbon-coated double-sided tape. In order to make them electrically conductive, they were171
then sputter coated with gold prior to imaging. Images were obtained using a Quanta 200F172
instrument (FEI, Hillsboro, OR, USA). The fiber diameter was determined with the aid of the173
ImageJ software (National Institutes of Health, Bethesda, MD, USA): at least 50 fibers were174
measured, and the results are reported as mean ± S.D.175
176
2.3.2 Differential scanning calorimetry177
Differential Scanning Calorimetry (DSC) was undertaken on a Q2000 DSC (TA Instruments, New178
Castle, DE, USA). Samples were heated from 20 – 300 °C at 10 °C min-1, under a 40 mL min-1 flow179
of N2 gas. Data analysis was carried out using the TA Universal Analysis software.180
181
2.3.3 X-ray diffraction182
X-ray diffraction (XRD) patterns were collected using a Miniflex 600 diffractometer (Rigaku,183
Tokyo, Japan). The instrument produces Cu Kα radiation at 40 kV and 15 mA; patterns were 184
recorded in the 2Ɵ range 4 to 40 °C at 5° min-1185
186
2.3.4 Infrared spectroscopy187
Infrared (IR) spectroscopy was performed on a Spectrum 100 FTIR spectrometer (Perkin Elmer,188
Waltham, MA, USA) over the range 650 – 4000 cm-1 and at a resolution of 1 cm-1.189
190
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2.3.4 Molecular modeling191
In vacuo molecular mechanics calculations were performed using HyperChem version 8.0192
following the methodology described in the literature (Lopez et al., 2014). In brief, the193
structures of the individual compounds were first drawn in ChemBioDraw Ultra 13.0. Decameric194
PVP and PCL oligomers were selected as representative of the polymers. These were then195
incorporated into HyperChem, and trial structures generated based on preset bond196
angles/lengths, with all hydrogen atoms explicitly included. Initial minimisations were197
performed using the MM+ forcefield, followed by a full energetic minimization in AMBER3. Full198
details may be found in our previous work (Lopez et al., 2014).199
200
2.4 In vitro drug release assays201
2.4.1 Preparation of the model for release studies202
The design and validation of the PK-Eye model has been previously reported (Awwad et al.,203
2015). Briefly, the 2-compartment model (see Figure 2) is fabricated from polyacrylate with204
anterior (200 μL) and posterior (4.2 mL) cavities. A washer with a Visking membrane (molecular 205
weight cut off: 12 – 14 kDa) separates the two compartments. An inlet port into the posterior206
cavity near the membrane allows a ocular mimicking flow to be established through the model.207
An outlet port is present in the anterior cavity of the model which mimics ocular outflow and is208
used for continuous sampling. An injection port is present in each cavity. Aliquots can be209
collected from the outlet port of the anterior cavity or from the injection port of the posterior210
cavity.211
212
Prior to each experiment, the model was unscrewed and a washer with a fresh Visking213
membrane placed inside the model. A sample (ca. 6 × 7 mm; mass 7.0 ± 2.1 mg (PVP) and 5.7 ±214
3.4 mg (PCL)) cut from the fiber mat was placed in the posterior cavity and the model was215
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reassembled. For these studies, both anterior and posterior cavities of the model were filled216
with phosphate buffered saline (PBS; pH 7.4) through the injection port. The inlet port was217
connected to a 16 channel peristaltic pump and PBS flowed through the model at a flow rate of218
2.0 μL min-1. Samples were collected from the anterior chamber and filtered through a 0.22 μm 219
filter before analysis using high-performance liquid chromatography (HPLC).220
221
2.4.2 Quantification of drug release222
HPLC was used to determine the drug concentration in the aliquots collected from the PK-Eye223
model. A calibration curve was first constructed for each drug, and the concentrations of224
unknown samples were back calculated from these data. Samples from each time point were225
evaluated in triplicate and the mean and standard deviation (S.D.) were determined. Three226
independent experiments were conducted for each formulation, and the results are reported as227
mean ± S.D. Different HPLC methods were developed for each drug (Table 2), together with a228
bespoke method to permit simultaneous analysis of all three active ingredients (Tables 2 – 4).229
All analyses were undertaken using a Agilent 1200 series HPLC (Agilent Technologies Inc, Santa230
Clara, CA, USA) equipped with Chemstation software (Agilent). The rate constants (k) and half-231
life (t1/2) of each drug were calculated by plotting the results in OriginPro. First-order kinetic232
rate constants (k) were derived from the monoexponential curve and half-lives as 0.693/k. The233
rate constants of zero-order release profiles were calculated as concentration–time and half-234
lives from the initial concentration [A] using [A]/2k.235
236
237
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Table 2: The HPLC conditions used to analyse drug release.238
Properties ACY CIP B12 All 3 drugs
Molecular
weight (g/mol) 225.2 331.3 1,355.3 N/A
Water solubility
(mg/mL) 2.5 (37 °C)
a 6.7 (20 °C)b 12.5c N/A
Calibration curve
details
500 ug/mL serial
diluted to 0.24
ug/mL
R2: 0.995
Slope: 58.3
500 ug/mL serial
diluted to 0.49
ug/mL
R2: 0.991
Slope: 64.8
1000 ug/mL serial
diluted to 0.49
ug/mL
R2: 0.999
Slope: 6.83
As per
individual
drugs
Column
Reverse phase
Synergi Polar-RP
Phenomenex 4 um,
15 cm column
Reverse phase
Synergi Polar-RP
Phenomenex 4
um, 15 cm
column
Reverse phase
Synergi Polar-RP
Phenomenex 4
um, 15 cm
column
Reverse phase
Synergi Polar
column 250 x
4.6 mm, 4 um,
15 cm column
Wavelength (nm) 254 280 278 See Table 3
Injection volume
(µL) 10.0 10.0 10.0 10.0
Flow rate
(mL/min) 1.0 1.0 1.0 1.0
Column
temperature (°C) 30 30 30 40
Method Isocratic Isocratic Isocratic Gradient, seeTable 4
Buffers
Buffer A: 0.1%
ammonium acetate
in water;
Buffer B:
acetonitrile.
A:B 95:5 v/v
Buffer A: 2%
aqueous acetic
acid solution
Buffer B:
acetonitrile.
A:B 84:16 v/v
Buffer A: 70%
PBS, pH 7.4;
Buffer B: 30%
methanol
A:B 70:30 v/v
Buffer A as 20
mM PBS, pH 4;
Buffer B:
acetonitrile
See Tables 3-4
Retention time
(mins) 3.1 4.7 2.13
ACY: 6.5
CIP: 14.1
B12: 13.5
Sources: a http://www.drugbank.ca/drugs/DB00787; b hydrochloride form, (Caco et al., 2008);239
c http://www.drugbank.ca/drugs/DB00115240
241
Table 3: The gradient method used to analyse acyclovir, ciprofloxacin and cyanocobalamin simultaneously in HPLC.242
Time (mins) % acetonitrile (v/v)
0 5
4 5
10 40
20 80
20.1 5
25 5
243
244
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Table 4: UV absorbance wavelengths used for the gradient method detailed in Table 3.245
Time (mins) Wavelength (nm)
(nm)0 255
11 360
12.75 279
246
3. Results and discussion247
3.1 Fiber production248
3.1.1 PVP fibers249
A range of optimization experiments were initially undertaken in which the processing250
parameters (voltage, polymer concentration, solvent system) were systematically varied. As a251
result, the conditions listed in Section 2.2 were adopted for further studies. These permitted252
fibers to be prepared with PVP and all three active ingredients. SEM images of the PVP systems253
are given in Figure 3, and details of the fiber sizes in Table 5.254
255
Figure 3: SEM images of (a) PVP-ACY; (b) PVP-CIP; (c) PVP-B12; and (d) PVP-ABC (containing all three drugs).256
257
In all cases, cylindrical fibers can be seen to have formed. For the single-drug fibers, there is258
evidence for incomplete evaporation of solvent during the electrospinning process, in the form259
of merged fibers. However, there appears to be no significant amounts of beading present, and260
the PVP-ABC fibers with all three drugs having been loaded all have smooth cylindrical261
morphologies with no evidence of any abnormalities.262
263
No clear trends emerge from the diameter data: there is no obvious relationship between the264
drug content in the fibers (PVP-ABC > PVP-ACY > PVP-CIP > PVP-B12) and their diameters (PVP-265
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ABC > PVP-B12 > PVP-CIP > PVP-ACY). It is presumed that both the amount of API present in266
solution and the effect each has on solution parameters such as viscosity and conductivity267
affect the diameter of the fibers obtained, thus leading to these complex patterns. Higher drug268
loadings appear to result in somewhat more homogenous distributions of fiber diameters.269
270
Table 5: The diameters of the PVP and PCL fibers prepared.271
Fiber Fiber diameter (nm) Diameter uniformity (% RSD)
PVP-ACY 267 ± 48 17.2
PVP-CIP 762 ± 159 20.8
PVP-B12 921 ± 232 25.2
PVP-ABCa 932 ± 137 14.7
PCL-ACY 623 ± 294 46.9
PCL-CIP 768 ± 210 27.3
PCL-B12 744 ± 267 35.9
PCL-ACb 478 ± 104 21.8
PCL-ABCa 631 ± 344 54.5
a Containing all three drugs; b containing ACY and CIP.272
273
3.1.2 PCL fibers274
PCL fibers could not be formed using the chloroform and DMF solvent system used with PVP275
because the resultant solution was too viscous, leading to clogging of the spinneret. A range of276
alternatives was explored, and 1:1 v/v chloroform/methanol was found to be suitable for PCL.277
The fibers produced are depicted in Figure 4, and their diameters summarized in Table 5.278
279
Figure 4: SEM images of (a) PCL-ACY; (b) PCL-CIP; (c) PCL-B12; (d) PCL-AB; and, (e) PCL-ABC280
281
In all cases, the fibers can be seen to have cylindrical morphologies. The PCL-ACY fibers show282
rough and/or wrinkled surfaces in places, and high degrees of curvature. The PCL-CIP sample283
has similar morphology, and additionally some particles (presumably of CIP) can be seen on the284
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fiber surfaces (see Figure 3(b), inset). The PCL-B12 fibers are flattened owing to incomplete285
solvent evaporation during electrospinning. The PCL-AB fibers are smooth but again some286
particles can be seen on the fiber surface (Figure 3(d), inset), although these are much smaller287
and less frequent than those seen with PCL-CIP. PCL-ABC comprises fibers with wrinkled288
surfaces, presumably as a result of incomplete solvent evaporation during electrospinning. In289
general, the multi-drug fibers have higher quality than the single-drug systems, being virtually290
free of particles (a very few may be seen upon very close inspection of the PCL-AB291
micrographs). As before, there is no direct correlation between the fibers’ API content (PCL-ABC292
> PCL-AC > PCL-ACY > PCL-CIP > PCL-B12) and their diameters (PCL-CIP > PCL-B12 > PCL-ABC >293
PCL-ACY > PCL-AC). The same is true for the diameter distributions, and the homogeneity of the294
fiber population cannot be directly related to the API present or the API concentration.295
296
3.2 Physical form characterisation297
The fiber sets were investigated using differential scanning calorimetry (DSC) and X-ray298
diffraction (XRD) to probe the physical form of the drug in the fibers. DSC data are presented in299
Figure 5.300
301
(a) (b) (c)
Figure 5: DSC data for (a) the starting materials, and electrospun fibers of (b) PVP and (c) PCL. Data have been normalised to the302
most intense peak in each trace for ease of comparison.303
304
16
The raw polymers PVP and PCL are amorphous and semi-crystalline respectively. PVP shows a305
broad endotherm below 150 °C in its thermogram, corresponding to dehydration. PCL exhibits a306
clear melt at ca. 60 °C. The trace for ACY has a shallow endotherm below 175 °C, which might307
be attributed to dehydration, and then a melt corresponding to the most stable form II (ACY is308
known to exhibit complex polymorphism (Lutker et al., 2011)) is visible at ca. 257 °C. The latter309
appears to be followed by an exotherm, which might indicate degradation. CIP is also a310
crystalline material; melting is clearly visible at ca. 256 – 257 °C. The DSC data of B12 depict an311
endothermic peak corresponding to water loss below 150 °C and a complex series of peaks312
around 220 – 275 °C which are believed to correspond to degradation.313
314
The drug-loaded PVP fibers are all amorphous: the only distinct features in the DSC traces are315
broad endotherms corresponding to the loss of water. No melting events can be seen.316
Considering the PCL systems, in all cases, the PCL melting endotherm is present at ca. 57 – 58317
°C, reduced slightly from the pure polymer value as a result of the plasticizing influence of the318
small-molecule APIs incorporated. A close inspection of all the DSC traces for the PCL fibers319
suggests traces of crystallinity are present (see Figure 5(c)); a particularly marked endothermic320
peak is present for the ACY fibers at 252 °C, indicating the possible presence of form VI of ACY321
(Lutker et al., 2011).322
323
To investigate further the physical form of the drug in the fibers, X-ray diffraction (XRD)324
measurements were undertaken (see Figure 6). The CIP and ACY starting materials are325
evidently crystalline, while B12 is amorphous. PVP is also amorphous, and PCL is semi-326
crystalline is nature. These observations all concur with the literature. The PVP fibers largely327
appear to contain the drug in the amorphous physical form, as proven by a lack of Bragg328
reflections in the patterns. For PVP-ABC however, there is evidence for some crystalline329
17
material present, with small Bragg reflections (believed to correspond to ACY) clearly visible330
between 20 and 30°. The XRD patterns of the PCL fibers show the distinctive reflections of PCL,331
with some additional peaks also visible. These are few and low intensity, meaning that the332
nature of these is not completely clear, but those in PCL-ABC correspond closely to those of the333
ACY raw material. In any case, it is clear that some crystalline material is present, in good334
agreement with the DSC data.335
336
337
(a) (b) (c)
Figure 6: XRD patterns for (a) the starting materials, and the fibers of (b) PVP and (c) PCL produced. The intensities have been338
normalised to the most intense reflection in each pattern for ease of comparison.339
340
3.3 Drug-polymer interactions341
The interactions between the drug and polymer were investigated using both IR spectroscopy342
and molecular modelling.343
344
3.3.1 IR spectroscopy345
IR spectra of the raw materials and fibers are presented in Figure 7.346
347
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(a) (b) (c)
Figure 7: IR spectra for (a) the starting materials, and electrospun fibers of (b) PVP and (c) PCL.348
349
An inspection of the data in Figure 7 reveals the IR spectra of the fibers to be dominated by the350
features of the polymer carrier. The spectra in Figure 7(b) are indistinguishable from that of351
PVP, and similarly those in Figure 7(c) show no significant differences from the PCL spectrum.352
This is not surprising given that the diagnostic vibration bands for the APIs occur over the same353
wavenumber range as those of the polymers (see Figure 7(a)), and also in many cases the drug354
loading is low (< 5 % w/w). As a result, it is not possible to say from these data whether there355
are any interactions between the APIs and polymers, although from their chemical structures it356
is thought that such interactions are likely to arise. To probe these possibilities in more detail,357
simple molecular models were constructed.358
359
3.3.2 Molecular modeling360
To evaluate the interactions between the drug molecules and the polymer in the fibers,361
molecular models of the APIs and polymers and the various combinations of drug and polymer362
were constructed using the HyperChem software. A PVP or PCL decamer (10-mer) were taken363
as representative of the polymers, and both these structure and those of the APIs were364
optimized. Suitable combinations of the energetically minimized structures were merged to365
create drug-polymer complexes. The drug-polymer composites were then themselves366
minimized, with the results shown in Figure 8.367
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368
The energetic contributions to the overall steric energy for both the drug-polymer complexes369
and the individual API and PVP or PCL decamers are presented in Table 6. Stabilization of the370
complexes is indicated by a negative difference (∆E) between the total steric energy of the 371
complex and the sum of the total steric energies of the individual molecules. The data reveal372
that all the drug/polymer complexes have negative ∆E values, demonstrating the possibility for 373
favorable secondary interactions to occur between the fiber components. The ∆E values for the 374
PVP systems are more negative than those with PCL, suggesting stronger interactions arise in375
the former case.376
377
378
Figure 8: Energy minimized structures of the polymer-drug complexes. The polymer is at the top of each image, and the drug at379
the bottom.380
381
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Table 6: The energetics of the optimized geometries in the polymer-drug complexes.382
System
Minimised energy contributions / kcal mol-1
Bond
stretching
Bond angle Torsional
van der
Waals
H-bonding ΣE ΔE 
ACY 0.296 3.150 1.002 1.172 -0.051 5.569 -
CIP 0.988 99.988 9.139 8.057 -0.006 118.166 -
B12 7.047 174.957 58.893 0.739 -0.301 241.336 -
PVP 4.337 82.689 46.017 -12.788 0.000 120.255 -
PCL 0.675 2.911 0.012 8.780 0.000 12.378 -
PVP-ACY 4.550 84.337 47.984 -24.382 -0.094 112.395 -13.429
PVP-CIP 5.137 179.346 56.773 -17.580 -0.006 223.669 -14.753
PVP-B12 11.688 257.214 103.517 -39.641 -1.036 331.742 -29.848
PCL-ACY 0.922 6.304 1.100 2.305 -0.136 10.496 -7.451
PCL-CIP 1.547 102.621 10.114 2.693 -0.039 116.936 -13.609
PCL-B12 9.844 177.507 55.995 -11.361 -0.412 231.573 -22.141
383
3.4 Drug release384
All experiments were performed using PBS (pH 7.4) as a vitreous substitute in the PK-Eye model385
to permit time-efficient screening of the various formulations. Samples were taken from the386
anterior cavity outflow, and the drug concentrations in these aliquots were used to calculate387
the content in the posterior cavity. A steady state condition is established relatively quickly for388
low molecular weight drugs so the solution drug concentrations are the same in both cavities.389
This assumption has been validated in a previous study (Awwad et al., 2015). The release data390
from the single drug-loaded fibers are given in Figure 9, and a summary of the calculated391
parameters for all the fibers can be found in Table 7.392
393
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Figure 9: Release kinetics of PVP and PCL fibers loaded with (a) ACY, (b) CIP, and (c) B12 in the PK-Eye. All results are displayed394
as mean ± S.D. from three independent experiments. The anterior drug concentration is shown on the left, and the drug395
clearance on the right.396
397
3.4.1 ACY release398
ACY is a potent systemic antiviral that is used for acute retinal necrosis because of its selectivity399
against the herpes simplex virus and the varicella-zoster virus. Direct ocular application has400
been found to be beneficial in controlling this type of aggressive retinitis within the first 48401
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hours, when systemic ACY has not reached the required therapeutic levels in the retina (Damico402
et al., 2012). Intravitreal anti-virals have been used since the early 1990s for the treatment of403
CMV and have also been used in acute retinitis necrosis (Tam et al., 2012). The intravitreal404
delivery of acyclovir is safe and well tolerated by rabbit retina, but its half-life in vivo is short405
(Damico et al., 2012; John, 2007; Peyman et al., 2008).406
407
When the ACY loaded PVP fibers were tested in the PK-Eye, the drug concentration displayed a408
mono-exponential decrease following first order kinetics (Figure 9(a)). The fibers led to an ACY409
residence time of 0.95 ± 0.12 days with a maximum concentration of 48.5 ± 23.5 μg/mL 410
observed after 23 hours. The PCL-ACY fibers gave a residence time of 3.67 ± 1.4 days, with the411
highest concentration of 40.4 ± 21.6 μg/mL seen after 88 h. When other anti-viral drugs (e.g.412
ganciclovir) were tested in the preliminary stages of PK-Eye development, their half-life was413
seen to be only a few hours (data not shown) which is consistent with human and animal data.414
Once in solution, low molecular weight drugs are eliminated quickly from the human eye and415
this is seen in the model. The data indicate the fibers prolong the release of acyclovir over 1 – 4416
days. For both sets of materials, around 70 – 80 % of the theoretical loading is released. PVP is417
more soluble than PCL in water, and thus might be expected to give much more rapid drug418
release. However, in the PK-Eye model, the small volumes and flow rates involved mean that419
the dissolution of PVP is slow, and it is to be presumed that a balance of polymer solubility and420
the strength of the polymer/drug interactions (the latter are stronger for PVP) influence the421
release kinetics.422
423
3.4.2 CIP release424
CIP has a wide spectrum of anti-Gram negative bactericidal activities and has been used in the425
treatment of many clinical infections (Hui et al., 2004). It is considered effective for the426
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treatment of intraocular infections and prophylaxis, and has also been found to be non-toxic to427
rabbit retina (Peyman et al., 2008). CIP has a molecular weight of 331.3 g/mol, and a terminal428
half-life of 4 – 5 days in rabbit eyes has been reported (Haghjou et al., 2013; Liu et al., 1998;429
Peyman et al., 2008). However, other studies report a half-life of 2.2 hours and 1 hour in430
normal and aphakic eyes (from which the lens has been removed) respectively (Pearson et al.,431
1993). Similar to ACY, CIP has poor water solubility at low pH. It is almost insoluble in neutral432
pH, while its solubility increases with increasing pH value (approximately 30 mg/mL at pH 11).433
434
Both the PVP-CIP and PCL-CIP fibers showed prolonged half-lives, with CIP clearance following435
first order kinetics (Figure 9(b)). PVP-CIP displayed an ocular residence time of approximately436
1.36 ± 0.4 days, with the highest drug concentration reaching 0.61 ± 0.35 μg/mL at 32 hours. It 437
took about 190 hours (approx. 8 days) for no drug to be detectable in the outflow liquid by438
HPLC. PCL-CIP showed a slight extension of half-life as compared to PVP-CIP, with a residence439
time of 2.1 ± 0.68 days. The highest concentration observed was 1.06 ± 0.47 μg/mL at 24 hours 440
and after around 190 hours release no further release was seen. Only 3.5 – 4 % of the441
theoretical loading was seen to be released with both polymers. This can perhaps be ascribed442
to the low solubility of CIP at pH 7.4, and the strong interactions between this API and both PVP443
and PCL indicated by molecular modelling. As for with ACY, we believe that a balance of drug444
and polymer solubility and drug/polymer interactions govern the release process.445
446
3.4.3 B12 release447
Deficiencies of cyanocobalamin, vitamin B12, have been connected with burning pain and448
foreign body sensations in the eyes (Shetty et al., 2015) and visual acuity (Doan and Chao,449
2014). B12 is also used in some eye drops (Santen Pharmaceutical Co, 2013). The PVP-B12 and450
PCL-B12 fibers (Figure 9(c)) presented the highest concentration of drug after around 30 hours451
24
(2.01 ± 0.79 μg/mL) and 21 hours (8.21 ± 4.7 μg/mL) respectively. B12 clearance from PK-Eye 452
with both sets of fibers followed first order kinetics, with a mono-exponential decrease. PVP-453
B12 had a slightly slower rate of release than PCL-B12, with observed residence times of 2.32 ±454
0.78 days and 0.80 ± 0.21 days respectively. This can possibly be ascribed to the stronger455
drug/polymer interactions calculated with PVP. Around 25% of the theoretical loading was456
released into solution.457
458
3.4.4 Multidrug systems459
The PCL-ABC fibers were also tested in the PK-Eye (Figure 10). The highest concentrations of460
ACY, B12 and CIP detected in the model were around 39.7 ± 2.4 μg/mL (17 hours), 14.3 ± 1.9 461
μg/mL (17 hours) and 3.6 ± 0.12 μg/mL (208 hours) respectively. With these fibers, both ACY 462
and B12 release followed first order kinetics while CIP followed zero order kinetics. The463
residence times for ACY, B12 and CIP were 1.4 ± 0.08 days, 6.16 ± 0.6 days and 2.99 ± 0.19 days.464
In terms of the theoretical loading, ca. 33 %, 50 % and 100 % of ACY, CIP, and B12 were465
released respectively. The PCL-ABC fibers release a greater percentage of their B12 and CIP466
loadings than the single-drug analogues, but rather less of the ACY loading. The percentages467
released correlate with the API solubilities (B12 > CIP > ACY), but inversely with the strength of468
interactions between the API and PCL. The reasons for this are not entirely clear, but it may be469
that the presence of multiple APIs in the fibers diminishes the importance of the PCL/API470
interactions and causes the solubility factor to become dominant in determining the amount471
released.472
473
474
475
476
25
Anterior concentration (μg/mL) Anterior drug clearance (%) 
Figure 10: Drug release kinetics from (a) PVP-ABC and (b) PCL-ABC in the PK-Eye. All results are displayed as mean ± S.D. from477
three independent experiments.478
479
Table 7: A summary of the kinetic parameters determined using the PK-Eye model.480
System Cumulative massreleased (µg)
Rate constant
(h-1) Half-life (d)
% of theoretical
loading released
PVP-ACY 248.4 ± 27.7 0.031 ± 0.004 0.95 ± 0.12 71.0
PVP-CIP 3.82 ± 0.05 0.022 ± 0.008 1.36 ± 0.4 3.51
PVP-B12 19.1 ± 1.9 0.014 ± 0.005 2.32 ± 0.8 26.2
PCL-ACY 543.7 ± 40.4 0.009 ± 0.004 3.67 ± 1.4 81.7
PCL-CIP 8.15 ± 0.1 0.015 ± 0.005 2.02 ± 0.7 3.75
PCL-B12 34.3 ± 4.1 0.038 ± 0.010 0.80 ± 0.2 23.3
PCL-ABC ACY 208.7 ± 12.4 0.021 ± 0.02 1.4 ± 0.08 33.2
CIP 94.0 ± 8.01 0.32 ± 0.03 6.16 ± 0.6 49.8
B12 125.6 ± 0.8 0.01 ± 0.0006 2.99 ± 0.19 99.9
481
4. Conclusions482
Two series of electrospun fibers were successfully prepared for ocular drug delivery483
applications. These were loaded with the acyclovir, ciprofloxacin, and cyanocobalamin, or484
combinations of these active ingredients. One set of fibers was prepared with485
poly(vinylpyrrolidone) (PVP) and the other with poly(caprolactone) (PCL). The fibers formed had486
generally cylindrical morphologies, although there was some evidence of residual solvent being487
present in the PVP systems, and for drug particles in the case of PCL. The PVP fibers appeared488
to contain the drug in the amorphous physical form, while some crystalline nature was retained489
in the PCL materials. The active ingredients and polymers can form favourable intermolecular490
26
bonds when combined. Drug release studies were performed in a representative in vitro model491
of the eye, and the fiber formulations found to result in half-lives of up to 6 days. These are492
much greater than those of pure small molecule drug solutions in the same model, thus493
suggesting that the strategy adopted in this work is a viable one for the generation of494
intravitreal implants.495
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